Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Mesoblast limited    MSB   AU000000MSB8

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Securities Exc…
10/11/2017 10/12/2017 10/13/2017 10/16/2017 10/17/2017 Date
1.71(c) 1.84(c) 1.88(c) 1.82(c) 1.75 Last
1 158 285 1 926 638 2 711 657 649 650 975 779 Volume
-1.44% +7.60% +2.17% -3.19% -3.85% Change
More quotes
Financials ( AUD)
Sales 2018 53,2 M
EBIT 2018 -73,6 M
Net income 2018 -104 M
Finance 2018 114 M
Yield 2018 -
Sales 2019 83,5 M
EBIT 2019 -51,0 M
Net income 2019 -43,9 M
Debt 2019 24,4 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 14,0x
EV / Sales2019 10,6x
Capitalization 861 M
More Financials
Company
Mesoblast Ltd. engages in the research, development, and market of pharmaceutical products.Its medicines target the cardiovascular conditions, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.The company was founded by Itescu Silviu on June 8, 2004 and... 
More about the company
Surperformance© ratings of Mesoblast limited
Trading Rating : Investor Rating :
More Ratings
Latest news on MESOBLAST LIMITED
10/02 MESOBLAST LIMITED : - End Stage Heart Failure Trial Completes Enrollment 28 Sept..
09/28 Clinical Trial of Mesoblast’s Cell Therapy in End-Stage Heart Failure P..
09/27 MESOBLAST : Presents corporate updates at global healthcare conferences
09/26 MESOBLAST : Presents Corporate Updates at Global Healthcare Conferences
09/25 Mesoblast Presents Corporate Updates at Global Healthcare Conferences
09/20 MESOBLAST LIMITED : Earnings Review and Free Research Report: Mesoblast Reported..
09/19 MESOBLAST : Successfully completes a$50.7 million entitlement offer
08/30 Mesoblast Operational Highlights and Financial Results for the Fourth Quarter..
08/29 MESOBLAST LIMITED : RIGHTS ISSUE: 1 new share @ 1.4 AUD for 12 existing shares
08/28 MESOBLAST LIMITED : - Cleansing Notice for Entitlement Offer
More news
Sector news : Biotechnology & Medical Research - NEC
06:48aDJJOHNSON & JOHNSON : Raises Guidance on Earnings Beat
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
09/29 Merck to stop development of hepatitis C treatments
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
10/15$MESO, $ICEL - Mesoblast Limited #MESO & Cellular Dynamics Internatio.. 
10/12Mesoblast Limited $MESO Earning Somewhat Favorable Press Coverage, Study Find.. 
10/07Mesoblast Limited $MESO Lifted to “Buy” at Zacks Investment Research  
10/06Somewhat Positive Media Coverage Somewhat Unlikely to Affect Mesoblast Limite.. 
10/06Somewhat Positive Media Coverage Somewhat Unlikely to Affect Mesoblast Limite.. 
More tweets
Qtime:128
News from SeekingAlpha
10/01 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 1, 2017
08/31 HEALTHCARE GAINERS / LOSERS AS OF 11 : 00 am
08/31 BIOTECH FORUM DAILY DIGEST : Oncology Concern Newlink Genetics In The Spotlight
08/31 Premarkt analyst action - healthcare
08/29 Mesoblast reports Q4 results
Chart MESOBLAST LIMITED
Duration : Period :
Mesoblast limited Technical Analysis Chart | MSB | AU000000MSB8 | 4-Traders
Technical analysis trends MESOBLAST LIMITED
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 3,28  AUD
Spread / Average Target 80%
EPS Revisions
Managers
NameTitle
Silviu Itescu Chief Executive Officer, MD & Executive Director
Brian Jamieson Non-Executive Chairman
Paul Hodgkinson Chief Financial Officer
Donna L. Skerrett Chief Medical Officer
Paul Simmons Head-Research & New Product Development
Sector and Competitors
1st jan.Capitalization (M$)
MESOBLAST LIMITED32.80%676
INCYTE CORPORATION14.00%24 562
QUINTILES IMS HOLDINGS INC31.30%21 366
LONZA GROUP64.29%20 140
CELLTRION, INC.--.--%19 069
ALNYLAM PHARMACEUTICALS, INC.228.53%11 181